Professor Paul Harnett,
Professor Paul Harnett is a medical oncologist who specialises in the management of breast and gynaecological cancers. Professor Harnett is Director of Cancer Services, WSLHD and the SWTCRC. He has a strong interest in nurturing collaborations to help establish multidisciplinary tumour programs from a systems perspective and continues to act as a champion for the inclusion of research as one of the core disciplines contributing to the MDT-based approach to cancer care.
His vision is to establish programs specific for each type of cancer, which would embed research as well as methodically encapsulate the patient’s experience, from screening and diagnosis through to multidisciplinary treatment, psychosocial and palliative care with the aim of developing better systems and leading to improved patient outcomes.
Professor Rosemary Balleine,
Centre Co-Deputy Director
Professor Rosemary Balleine is Leader of the Cancer Pathology Research Group at the Children’s Medical Research Institute (CMRI). She is a Fellow of the Royal College of Pathologists of Australasia, having specialised in Anatomical Pathology, and obtained a PhD from the University of Sydney in 1998 for research into hormone-resistant breast cancer.
Professor Balleine has worked for over 15 years as a Research Pathologist in translational cancer research. Immediately prior to joining CMRI, Professor Balleine was Clinical Director of Tissue Pathology and Diagnostic Oncology at the Institute of Clinical Pathology and Medical Research at Westmead. Her research expertise includes molecular profiling of cancer, familial cancer and pharmacogenomics.
Professor Anna deFazio,
Centre Co-Deputy Director
Professor Anna deFazio holds the Sydney-West Chair in Translational Cancer Research, University of Sydney, is Co-Director of the Centre for Cancer Research and heads the Gynaecological Oncology Research Laboratory at the Westmead Institute for Medical Research. She has a long-standing commitment to translational research with an emphasis on improving treatment outcomes for women with ovarian cancer. She completed her PhD at the Ludwig Institute for Cancer Research, University of Sydney, undertook postdoctoral studies at the Garvan Institute and established a program of ovarian cancer research at Westmead in 1995.
Anna leads a Cancer Institute NSW Program Grant, “INOVATe-Individualised Ovarian Cancer Treatment Through Integration of Genomic Pathology into Multidisciplinary Care” and is an investigator on a number of national and international collaborative consortia including the Australian Ovarian Cancer Study (AOCS), the Australasian Biospecimen Network (ABN-Oncology), the International Cancer Genome Consortium (ICGC), the Ovarian Cancer Association Consortium (OCAC) and the NSW PRIMe (Pharmacogenomics Research for Individualised Medicine) consortium.